Literature DB >> 31005415

N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.

Ulrika Ljung Faxén1, Lars H Lund2, Nicola Orsini3, Anna Strömberg4, Daniel C Andersson5, Cecilia Linde2, Ulf Dahlström4, Gianluigi Savarese6.   

Abstract

OBJECTIVE: The aim was to assess sex-specific differences in N-terminal B-type natriuretic peptide (NT-proBNP) regarding concentrations, predictors of high concentrations, and prognostic role, in a large and unselected population with chronic heart failure (HF) with preserved (HFpEF), mid-range (HFmrEF), and reduced ejection fraction (HFrEF). METHODS AND
RESULTS: In 9847 outpatients with HFpEF, HFmrEF, and HFrEF (49 vs. 35 vs. 25% females, respectively) from the Swedish HF Registry, median NT-proBNP concentrations were 1598 ng/L in females vs. 1310 ng/L in males in HFpEF, 1764 vs. 1464 ng/L in HFmrEF, and 2543 vs. 2226 ng/L in HFrEF (p < 0.05 for all). The differences persisted after multiple adjustment. The largest sex-difference in NT-proBNP levels was observed in HFpEF with sinus rhythm, where median concentrations were 1.4 folds higher in females (923 vs. 647 ng/L). Independent predictors of NT-proBNP levels (defined as above the different medians according to sex and HF phenotype) were overall consistent across sexes and EF. NT-proBNP levels were similarly associated with risk of all-cause death/HF hospitalization in both sexes regardless of EF.
CONCLUSION: Concentrations of NT-proBNP were higher in females across the EF spectrum, with larger relative differences in HFpEF with sinus rhythm. However, similar predictors of high levels were observed in both sexes. There were no sex-differences in the prognostic role of NT-proBNP. These findings support the use of NT-proBNP for prognostic purposes in chronic HF, regardless of sex.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ejection fraction; Heart failure; N-terminal pro-B-type natriuretic peptide; Sex; SwedeHF

Mesh:

Substances:

Year:  2019        PMID: 31005415     DOI: 10.1016/j.ijcard.2019.04.023

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications.

Authors:  Emily S Lau; Aleksandra Binek; Sarah J Parker; Svati H Shah; Markella V Zanni; Jennifer E Van Eyk; Jennifer E Ho
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

2.  Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies.

Authors:  Andrea K Roalfe; Clare J Taylor; Johannes C Kelder; Arno W Hoes; F D Richard Hobbs
Journal:  ESC Heart Fail       Date:  2021-03-23

3.  Exploring gender differences in trajectories of clinical markers and symptoms after left ventricular assist device implantation.

Authors:  Quin E Denfeld; Kenneth M Faulkner; Mary Roberts Davis; Beth A Habecker; Christopher V Chien; Jill M Gelow; James O Mudd; Shirin O Hiatt; Kathleen L Grady; Christopher S Lee
Journal:  Eur J Cardiovasc Nurs       Date:  2021-10-27       Impact factor: 3.593

Review 4.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

Review 5.  Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease.

Authors:  Milton Packer; Carolyn S P Lam; Lars H Lund; Mathew S Maurer; Barry A Borlaug
Journal:  Eur J Heart Fail       Date:  2020-06-26       Impact factor: 15.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.